A Phase I, Open-Label Study of the Relative Bioavailability of Evobrutinib Tablet Manufacturing Batches in Healthy Participants
Latest Information Update: 21 Oct 2025
At a glance
- Drugs Evobrutinib (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Merck KGaA
Most Recent Events
- 21 Oct 2025 New trial record